2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Hyperscale Data entered a note purchase agreement dated November 6, 2026 with an institutional investor for convertible notes with an aggregate face amount of $27,027,027.03, including original issue discount. The first note closed the same day, and the notes convert into Class A common stock at a discount to market price, which could dilute existing shareholders.
Initial note: $10,810,810.81 principal for a $10,000,000 purchase price, closed November 6, 2026
Second note: $5,405,405.41 principal for a $5,000,000 purchase price, expected on or around November 16, 2026
Conversion at the lower of $0.30 or a 10% discount to the lowest 5-day VWAP, with a $0.1025 floor; issuance capped at 19.99% of outstanding shares unless stockholders approve
Notes accrue 8% interest and mature February 5, 2027, extending to May 5, 2027 after stockholder approval
Mangoceuticals' sole Series B preferred holder approved terms for a new 8% Series D convertible cumulative preferred stock and an amendment to the Series B designation, which would allow the company to sell up to 1,000,000 shares at $10.00 each under Regulation A. The company said the instruments are not yet filed or effective and it may not proceed with the offering; the company also set its combined 2025 and 2026 annual meeting for December 30, 2026.
On November 2, 2026, the holder of all 50 outstanding Series B preferred shares approved the Series D terms and Series B amendment by written consent.
Proposed Series D offering: up to 1,000,000 shares at $10.00 per share under Regulation A; no sales will occur before the SEC qualifies the offering statement on Form 1-A.
Annual meeting set for December 30, 2026 in Dallas, Texas; record date is November 12, 2026.
Shareholder proposals and director nominations for the meeting are due by November 16, 2026.
Clean Energy Technologies, Inc. sold FuFront AI Pte. Ltd. a convertible promissory note with a principal amount of $2,000,000 for the same purchase price, with funding received and the transaction closed on November 4, 2026. The note carries 12% annual interest, matures October 3, 2027, and can convert into common stock at a discount to recent trading prices, which could dilute existing shareholders.
Principal of $2,000,000 at a purchase price of $2,000,000; closed November 4, 2026
Interest accrues at 12% per annum; note matures October 3, 2027
Convertible six months after issuance at 85% of the lowest traded price over the prior ten trading days
Conversion limited to 4.99% beneficial ownership, and to 2,432,004 aggregate shares absent Nasdaq Rule 5635(d) shareholder approval; holder deducts $1,750 per conversion for fees
RenX Enterprises exchanged $1,022,971.22 of principal and accrued interest under a February 12, 2026 senior convertible note for a new senior convertible note of $1,037,283.93 and a warrant to buy 644,944 shares, both issued November 2, 2026. The new note carries 10% interest and a 12-month maturity, and it can convert at $2.895 per share, with a possible alternate conversion price tied to a $0.534 floor once stockholders approve, which could add substantial share issuance for existing holders.
Exchanged $1,022,971.22 of the February 12, 2026 note for a new note of $1,037,283.93, equal to 110% of the prior note's outstanding principal.
New note bears 10% interest, matures in 12 months, and has an initial conversion price of $2.895 per share.
Alternate conversion, available after stockholder approval, is priced at the greater of a $0.534 floor and 92% of the lowest 10-day VWAP.
Warrant has a $2.67 exercise price and a six-year term; default interest rises to 18% per annum if an event of default occurs.
BioVie Inc. agreed on November 3, 2026 to sell shares and pre-funded warrants in a registered direct offering and common warrants in a concurrent private placement, with aggregate gross proceeds of approximately $4.74 million before fees and expenses. The offering closed on November 5, 2026, and the company intends to use the net proceeds for working capital and general corporate purposes. The deal adds shares and dilutive warrants, and the company has agreed to restrictions on new share issuances.
Registered direct offering: 960,000 shares at $1.60 per share plus 2,002,500 pre-funded warrants at $1.5999 each
Concurrent private placement: 2,962,500 common warrants exercisable at $1.70 per share, starting six months after issuance
Placement agent A.G.P./Alliance Global Partners receives a cash fee of 7.0% of gross proceeds
Company and directors and officers agreed to issuance and sale restrictions for 60 days after the November 5, 2026 closing
Silo Pharma, Inc. entered into securities purchase agreements on November 5, 2026, and closed a private placement with accredited investors on November 6, 2026. The company expects net proceeds of approximately $815,000 for working capital and general corporate purposes, and it agreed to register the resale of the shares and warrant shares with the SEC, which adds potential future share supply for existing shareholders.
Sold 136,005 shares of common stock at $1.50 per share
Issued pre-funded warrants for up to 430,661 shares of common stock at $1.4999 per warrant
Expected net proceeds of approximately $815,000 after placement agent fees and offering expenses
Must file a resale registration statement within 30 days of the November 5, 2026 registration rights agreement, with effectiveness targeted within 60 days (90 days if the SEC conducts a full review)
Reed's, Inc. entered into a third amendment to its senior secured loan with Whitebox-affiliated lenders and Cantor Fitzgerald, adding new liquidity and equity-contribution conditions. The company must receive at least $2,500,000 in cash equity contributions by November 20, 2026, or an Event of Default will occur, and it must also pay a $25,000 extension fee by that date. The company said a delay in its previously announced private placement pushed the expected closing to on or before November 20, 2026, and it has so far received $7,500,000 in gross proceeds from that placement.
Minimum liquidity covenant of not less than $11,000,000 in Cash / Inventory / AR Liquidity, tested at any time and monthly after the Increased Liquidity Period
New Event of Default if at least $2,500,000 in cash equity contributions is not received by November 20, 2026
Non-refundable $25,000 extension fee due on or before November 20, 2026; nonpayment is an Event of Default
Private placement agreement dated October 28, 2026; $7,500,000 gross proceeds received to date
TuHURA Biosciences borrowed an additional $1.5 million on November 2, 2026, under the revolving credit facility from its April 21, 2026 Loan Agreement with Parkview Holdings One LLC. The facility has a maximum availability of $50 million and matures on April 21, 2031, and the company says it will use the funds for general corporate purposes.
Draw of $1,500,000 received and borrowed on November 2, 2026
Revolving facility with Parkview Holdings One LLC has maximum availability of $50 million
Facility matures April 21, 2031; the Loan Agreement was originally entered into April 21, 2026
Filing notes potential conflicts of interest because the lender is an affiliate of the company's largest stockholder
Santander Holdings USA, Inc. (SHUSA) said it will redeem all 6,000 outstanding shares of its Series H Preferred Stock and the corresponding 6,000,000 depositary shares on December 15, 2026. Depositary shares will be redeemed at $25.00 each, and the redemption price excludes the regular quarterly dividend, which is payable separately on the same date to holders of record on November 30, 2026.
Redemption date: December 15, 2026, covering 6,000 preferred shares and 6,000,000 depositary shares.
Redemption price: $25.00 per depositary share, not including the declared quarterly dividend.
Quarterly dividend: $0.328125 per depositary share, payable December 15, 2026 to holders of record as of November 30, 2026.
Redemption agent: Broadridge Corporate Issuer Solutions, LLC; shares are held through DTC.
Gogo and its subsidiary GIH signed a third amendment to their 2021 credit agreement, converting $544.4 million of term loans into new 2026 Extended Term Loans that mature October 31, 2030. The amendment requires $75 million of prepayments through December 31, 2027 and sets a higher interest margin of 5.75% over SOFR, so shareholders gain more time on debt maturities but pay more in interest and face required debt repayments.
2026 Extended Term Loans of $544.4 million mature October 31, 2030; Initial Term Loans of $33.4 million mature April 30, 2028
Required prepayments: $25.0 million on the November 6, 2026 closing date, $30.0 million by December 31, 2026, and $20.0 million by December 31, 2027
Interest at SOFR plus 5.75% or an alternate base rate plus 4.75%; quarterly amortization begins March 31, 2027
Amendment adds certain foreign subsidiaries as guarantors and grants additional collateral on a pari passu basis with the HPS Credit Agreement
Health In Tech, Inc. issued a second promissory note to investor YA II PN, Ltd. on November 2, 2026, with a principal amount of $3.0 million, which provided gross proceeds of $2.85 million after a 5% purchase price discount. The notes are convertible into Class A common stock at a fixed price of $1.5735 per share and can be converted into shares that could dilute existing holders, with an Exchange Cap of 13,100,378 shares that the company is seeking stockholder approval to exceed at its November 10, 2026 annual meeting.
Second promissory note issued November 2, 2026: $3.0 million principal, $2.85 million gross proceeds after 5% discount
Notes mature February 18, 2028, bear 8.75% annual interest (18% after certain defaults), and carry a 4% payment premium unless paid via stock sale proceeds
Conversion price fixed at $1.5735 per share with a floor price of $0.204; Exchange Cap is 13,100,378 shares, about 19.99% of outstanding Class A and Class B common stock
Company seeks stockholder approval to issue shares above the Exchange Cap at its annual meeting on November 10, 2026
Delta Air Lines completed a public offering of $500 million in 5.500% notes maturing November 6, 2029, on November 6, 2026. The company said it will use part of the proceeds to repay about $391 million of Payroll Support Program loan borrowings, about $70 million of aircraft-secured equipment notes, and, with cash on hand, about $39 million of pass through certificates, with any remainder for general corporate purposes. The filing adds new unsecured debt to the balance sheet while reducing several existing obligations.
Notes: $500 million aggregate principal, 5.500% coupon, maturing November 6, 2029
Interest paid semi-annually on May 6 and November 6, starting May 6, 2027
Proceeds to repay about $391 million Payroll Support Program loan, about $70 million equipment notes, and about $39 million pass through certificates
American Healthcare REIT entered into a new at-the-market equity sales agreement allowing it to sell up to $1.75 billion of common stock through a group of sales agents and forward purchasers. The company terminated its prior program, which had about $170 million left unsold, and says it will use any net proceeds for general corporate purposes, which may include future investments.
Agreement allows sales of common stock with an aggregate gross sales price of up to $1,750,000,000, replacing the prior program dated February 27, 2026.
About $170,134,000 remained unsold under the prior sales agreement when it was terminated.
Agents may receive a commission of up to 2.0% of gross sales price; shares are sold under a shelf registration statement on Form S-3 dated August 12, 2024.
Proceeds would go to the Operating Partnership for general corporate purposes, which may include potential future investments.
Silgan signed a consent to its credit agreement with Wells Fargo as administrative agent, letting lenders designate a new subsidiary, Silgan Metal Packaging LLC, as an unrestricted subsidiary. The change supports the planned contribution of several container and closure businesses to that entity under the October 17, 2026 Transaction Agreement. The filing gives no financial results or deal value, so the near-term effect on shareholders is not quantified here.
Consent to Amended and Restated Credit Agreement dated November 6, 2026, with Wells Fargo Bank, National Association, as Administrative Agent
Silgan Metal Packaging LLC (MetalCo) to be designated an Unrestricted Subsidiary, releasing it as a guarantor under the credit agreement
Business Contribution tied to the Transaction Agreement dated October 17, 2026 with A-VL Holdco, LP
If the MetalCo Transactions do not close, MetalCo and its subsidiaries will cease to be Unrestricted Subsidiaries
Profusa, Inc. entered into Amendment No. 4 to its Note Modification and Conversion Agreement with holder NorthView Sponsor I LLC on November 5, 2026. The amendment sets a $0.20 floor on the conversion price for the note, which has an original principal amount of up to $2,500,000. The change could result in a larger number of shares being issued to the holder on conversion, which may dilute existing shareholders.
Amendment No. 4 dated November 5, 2026 sets conversion price at the greater of $0.20 Floor Price or the prior trading day's Nasdaq closing price
Conversion shares are calculated as principal multiplied by 122%, divided by the conversion price, unchanged by the amendment
The prior Amendment No. 3 of August 12, 2026 set the conversion price at the greater of $4.28 or the prior trading day's closing price
Original note principal amount of up to $2,500,000, with the agreement first entered April 24, 2026
Energy Transfer LP priced $2.7 billion of senior notes in three equal $900 million tranches, due 2032, 2037 and 2057, with coupons of 5.450%, 5.900% and 6.550%. The offering is expected to settle on November 20, 2026, and the net proceeds of about $2.68 billion (before offering expenses) are intended to refinance existing debt, including commercial paper and revolving credit facility borrowings, and for general partnership purposes.
Three $900 million tranches: 5.450% notes due 2032, 5.900% notes due 2037 and 6.550% notes due 2057.
Prices to the public were 99.972%, 99.719% and 99.862% of face value, respectively.
Expected settlement date is November 20, 2026, subject to customary closing conditions.
Net proceeds of about $2.68 billion will refinance existing indebtedness and fund general partnership purposes; several underwriters' affiliates are lenders under the revolving credit facility and may receive a share of the repayment.
Enova International said subsidiary OnDeck Asset Securitization IV, LLC intends to offer $500,251,000 of Series 2026-2 fixed rate asset-backed notes in a private securitization backed by small business loans originated or purchased by its subsidiary ODK Capital, LLC. Closing is anticipated on or about November 13, 2026, subject to market and customary conditions, so the offering may not be completed as contemplated or at all. The notes will not be obligations of or guaranteed by Enova or OnDeck, and OnDeck expects to use substantially all proceeds for loan purchases from affiliates and general corporate purposes.
Four classes total $500,251,000: Class A $190,095,000 at 5.81%, Class B $118,744,000 at 6.15%, Class C $100,050,000 at 6.73%, Class D $91,362,000 at 8.57%.
Anticipated Kroll Bond Rating Agency ratings range from AA (sf) for Class A to BB- (sf) for Class D.
Notes are offered only to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S, and are not registered under the Securities Act.
Legal final payment date is December 19, 2033; the company announced the offering on November 3, 2026.
ACRES Commercial Realty Corp. entered into a Seventh Amendment to its Master Repurchase and Securities Contract Agreement with Morgan Stanley Mortgage Capital Holdings, which extends the agreement to November 2027 and modifies certain financial covenants in the related guaranty. The filing describes a routine financing amendment and does not disclose a borrowing amount, pricing, or fee figures beyond a reference to an unspecified Extension Fee.
Amendment dated November 2, 2026 extends the Morgan Stanley agreement to November 2027.
Company, as guarantor, agreed to amend certain financial covenants in its guaranty to Morgan Stanley.
Subsidiary ACRES Real Estate SPE 10, LLC is the seller; payment of an Extension Fee was due on or before November 3, 2026, amount not stated in the filing.
MediaCo Holding entered a Third Amendment to its First Lien Term Loan Credit Agreement, moving the maturity of its Delayed Draw Term Loans from October 31, 2026 to the earliest of November 30, 2026 or certain acceleration or debt-related triggers. The lender agent acknowledged that defaults or events of default have occurred and are continuing, and all parties reserved their rights, signaling significant financial stress for shareholders.
Delayed Draw Term Loan maturity extended from October 31, 2026 to no later than November 30, 2026
Agent acknowledged that certain defaults or events of default have occurred and are continuing
Agent and lenders reserved all rights and remedies under the Credit Agreement
Company released the agent and lenders from known claims arising on or before the amendment date
Zenas BioPharma filed a new prospectus supplement for an at-the-market offering of up to $200 million in common stock through Jefferies LLC, and ended the earlier program, under which it had sold about $153.2 million of shares with about $46.8 million unsold. The filing is a routine share-sale mechanism, and any sales would dilute existing shareholders, though the filing does not state whether or when any shares will be sold.
New prospectus supplement filed November 6, 2026, for up to $200,000,000 of common stock under the October 8, 2025 Sales Agreement with Jefferies LLC
Prior program terminated: about $153.2 million sold and about $46.8 million unsold at filing date
Shares to be offered under the existing Form S-3ASR registration statement, which became automatically effective upon filing
Ropes & Gray LLP legal opinion filed as Exhibit 5.1
NB Bancorp, Inc., the holding company of Needham Bank, issued $100 million of 7.50% fixed-to-floating subordinated notes due 2036 to institutional investors on November 6, 2026, at 100% of principal. The company estimates net proceeds of approximately $98,265,004.75 and plans to use them for general corporate purposes, including at least $30 million to increase the bank's Tier 1 capital, and the notes are intended to count as Tier 2 capital.
$100 million principal, maturing November 15, 2036, issued at 100% of principal in a private placement
Fixed rate of 7.50% until November 15, 2031, then resets quarterly to three-month SOFR plus 305 basis points
Estimated net proceeds of approximately $98,265,004.75; at least $30 million to be contributed to Needham Bank
Notes rated BBB- by Kroll Bond Rating Agency; Piper Sandler & Co. was sole placement agent
GATX Corporation agreed under an underwriting agreement dated November 2, 2026 to sell $300 million of 5.950% Senior Notes due 2036, and issued the notes to the underwriters on November 6, 2026. The filing describes a debt issuance rather than a change in operations, so its main significance for shareholders is the added long-term borrowing.
Principal amount: $300 million of 5.950% Senior Notes due 2036
Underwriting agreement dated November 2, 2026, with BofA Securities, Citigroup Global Markets and Morgan Stanley & Co. as representatives
Notes issued and delivered to underwriters against payment on November 6, 2026
Sold under shelf registration statement on Form S-3 (Registration No. 333-286436)
aTyr Pharma filed a prospectus supplement allowing it to sell common stock worth up to $79,994,251 from time to time under an existing open market sale agreement with Jefferies LLC. The filing sets up potential share issuance that could dilute existing shareholders, though the filing does not state how much stock has been or will be sold.
Maximum aggregate offering price of up to $79,994,251 under the Sales Agreement with Jefferies LLC, dated April 22, 2022, as amended December 23, 2024
Offering is made under Form S-3 shelf registration (File No. 333-289360), filed August 7, 2025 and declared effective August 18, 2025
Cooley LLP legal opinion on the legality of the shares filed as Exhibit 5.1
NextNRG, Inc. closed a debt exchange on November 3, 2026, in which CEO Michael D. Farkas exchanged $7,000,000 of notes, interest and guarantee fees for 7,000 shares of newly designated Series D Convertible Voting Preferred Stock. The company says this reduces indebtedness and supports its efforts to meet Nasdaq's $2.5 million stockholders' equity requirement, but the filing states that the exchange alone does not satisfy that requirement. The Series D shares accrue an 18% annual cumulative dividend, are convertible into common stock at an initial $2.20 price, and carry voting rights, which may dilute common shareholders.
Exchange covered $3,629,924 in note principal, $2,749,169 in accrued interest and $620,907 in guarantee fees, with the closing on November 3, 2026
7,000 Series D shares carry an initial stated value of $1,000 per share, with a cumulative dividend of 18% a year compounding monthly
Initial conversion price is $2.20 per share; conversion and voting are capped at 1,684,224 shares, or 9.99%, until the Cap Release Date
Nasdaq requires at least $2.5 million in stockholders' equity; the exchange alone does not satisfy that requirement, and the company awaits a Nasdaq Hearings Panel decision
Public Storage Operating Company, a subsidiary of Public Storage, completed a $500 million offering of 5.600% Senior Notes due November 15, 2036, guaranteed by Public Storage. The filing describes new long-term unsecured debt with covenants limiting secured and unsecured borrowing and requiring unencumbered assets of at least 125% of unsecured indebtedness.
Principal amount of $500 million; interest at 5.600% per year, accruing from November 6, 2026
Interest payable semi-annually on May 15 and November 15, starting May 15, 2027; maturity November 15, 2036
Notes are unsecured and rank equally with existing and future unsecured debt of the issuer; redeemable at a make-whole price, or at 100% of principal from August 15, 2036
Offering made under a Form S-3 shelf registration; prospectus supplement dated October 29, 2026
Janus Living, Inc. closed a registered underwritten public offering of 30,187,500 Class A-1 common shares on November 6, 2026, including the underwriters' full exercise of their option to buy 3,937,500 additional shares. The filing does not state the offering price or the proceeds, and the issuance adds shares that will dilute existing holders' ownership.
Offering closed November 6, 2026 with 30,187,500 Class A-1 common shares, $0.01 par value
Underwriters exercised their option in full for 3,937,500 additional shares
Underwriting Agreement dated November 4, 2026 with BofA Securities, J.P. Morgan, Wells Fargo and Goldman Sachs as representatives
Repligen closed private exchange and subscription transactions on November 6, 2026, issuing $1.0 billion of 0.25% Convertible Senior Notes due 2031. About $541.4 million of the new notes swapped out $456.8 million of its 1.00% notes due 2028, and $458.6 million was sold for cash. The filing shows the company took on new debt with a lower coupon and a conversion price about 20% above the October 29, 2026 closing price, which could mean future share dilution if holders convert.
Issued $1.0 billion of 0.25% Convertible Senior Notes due November 1, 2031, with interest paid semi-annually starting May 1, 2027
Exchanged $456.8 million of 1.00% 2028 notes for $541.4 million of new notes; $143.2 million of 2028 notes remain outstanding
Initial conversion price of about $226.37 per share, roughly 20% above the $188.64 closing price on October 29, 2026
Up to 5,301,100 shares of common stock may be issued on conversion, including make-whole additional shares
PowerCompute entered into a Fourth Amendment to a Secured Promissory Note with Brown Family Enterprises LLC, effective October 31, 2026, extending the maturity of a $1,250,000 loan from December 31, 2026 to December 31, 2027. The filing describes a debt maturity extension only and does not state any change to the loan amount or other terms, so it defers repayment pressure by one year.
Loan principal amount: $1,250,000 from Brown Family Enterprises LLC
Maturity date extended from December 31, 2026 to December 31, 2027
Amendment dated October 31, 2026, agreement entered November 2, 2026
60 Degrees Pharmaceuticals agreed on November 5, 2026, to offer inducement letters to holders of existing warrants, who would exercise 584,492 shares at a reduced $0.90 per share. The company expects gross proceeds of $526,042.80 before fees, and in exchange will issue new unregistered warrants for up to 1,168,984 shares, which could add to share count and dilute existing shareholders.
Holders would exercise existing warrants for 584,492 shares at a reduced $0.90 per share, with expected gross proceeds of $526,042.80 before fees.
New warrants for up to 1,168,984 shares, equal to 200% of the exercised shares, carry a $0.90 exercise price and cannot be exercised before stockholder approval.
H.C. Wainwright & Co. is placement agent, receiving a 7.5% cash fee, a 1.0% management fee and placement agent warrants for 43,837 shares.
Closing is expected on or about November 9, 2026, subject to customary conditions.
On November 5, 2026, EVERTEC's subsidiary Evertec Group, LLC refinanced its $387.8 million Term A loan and replaced its revolving facility under a seventh amendment to its credit agreement with Truist Bank as agent. Both facilities now mature on November 5, 2031, and revolving commitments rose from $200.0 million to $300.0 million. The company said pricing fell 25 basis points, and it paid the transaction costs with cash on hand.
Term A facility of $387.8 million refinanced through a cashless roll and now matures November 5, 2031, subject to a springing maturity tied to Term B loans.
Revolving commitments increased from $200.0 million to $300.0 million, with an additional $100 million incremental commitment fungible with the existing revolver.
Interest margins range from 1.25% to 2.25% for SOFR term loans and 0.25% to 1.25% for alternate base rate loans, based on the Total Net Leverage Ratio.
Term B loans maturing October 30, 2030 had $875 million outstanding as of November 6, 2026, and the filing says their terms are not affected.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.